MaxCyte

MaxCyte FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of MaxCyte (MXCT) as of Oct 20, 2026 is 81.06 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 71.27 % — a change of 13.74% (higher).

FCF Conversion

81.06 %

YoY

13.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of MaxCyte is 2025 81.06 % . FCF Conversion Rate (FCF/EBITDA) of MaxCyte was 2024 71.27 % . It decreases by 13.74% higher compared to the previous year.

The MaxCyte FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
126.25 USD
Jan 1, 2019
78.12 USD
Jan 1, 2020
91.86 USD
Jan 1, 2021
76.06 USD
Jan 1, 2022
141.11 USD
Jan 1, 2023
66.94 USD
Jan 1, 2024
71.27 USD
Jan 1, 2025
81.06 USD
The MaxCyte FCF Conversion history
YEARFCF ConversionYoY
81.06 %+13.74%
71.27 %+6.47%
66.94 %-52.56%
141.11 %+85.52%
76.06 %-17.20%
91.86 %+17.58%
78.12 %-38.12%
126.25 %+21.71%
103.73 %+35.89%
76.34 %+301.25%
19.02 %-83.14%
112.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

FCF Conversion Rate (FCF/EBITDA) of MaxCyte is 81.06 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of MaxCyte changed from 71.27 % to 81.06 %, representing a 13.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) MaxCyte since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s MaxCyte with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — MaxCyte

All Key Metrics — MaxCyte